NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), which is characterised by necroinflammation ...

Identifying proteomic signatures of insulin resistance in fasting muscle offers insights for personalized type 2 diabetes ...

Hirudin ameliorates renal interstitial fibrosis via regulating TGF-β1/Smad and NF-κB signaling in UUO rat model ... Puerarin ameliorates the ferroptosis in diabetic liver injure through the JAK2/STAT3 ...

JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered using Juvena's proprietary JuvNET platform, an AI ...

Liver injury remains a critical global health issue as it can lead to severe complications such as fibrosis, cirrhosis, and hepatocellular carcinoma.

The study’s results demonstrated that FGF21 was effective at causing signaling in the model species that changed the liver’s metabolism. In doing so, the liver’s fat was lowered and the fibrosis was ...

Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment leads ...

The final, formatted version of the article will be published soon. Background: Liver fibrosis is a chronic condition marked by scar tissue accumulation in the liver that impairs function. Shikimic ...

Mechanisms of fibrosis have focused on hepatic stellate cells, which become fibrogenic myofibroblasts during injury through ‘activation’, and are at the nexus of efforts to define novel drug targets.

Activation of the sterol regulatory element-binding proteins (SREBPs), a step regulated by a cluster of ER-resident proteins, Insig-1, Insig-2 and SCAP, is rate limiting in hepatic de novo lipogenesis ...